Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Florbetapir (18F) PET Imaging in Japanese AD, MCI, and Healthy Subjects
NCT01662882Phase 3Completed
- Sponsor
- Avid Radiopharmaceuticals
- Start
- Oct 2012
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of florbetapir (18F) in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) (3 arms), sponsored by Avid Radiopharmaceuticals. Primary endpoints: Qualitative Amyloid Image Assessment and Mean Cortical to Cerebellum Standardized Uptake Value Ratio. Started Oct 2012; status: completed.
02
Drugs
florbetapir (18F)
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT01662882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01662882.